risk of prostate, breast, lung and colorectal cancers, and childhood leukemia. IGFBP-3 can inhibit cell growth and stimulate death through formation of complexes with IGF-I and IGF-II that prevent activation of the IGF-I receptor to stimulate proliferation and survival.

The current invention embodies a novel mechanism of action for IGFBP-3: direct inhibition of cell growth and stimulation of cell death through a mechanism that is independent of IGF-I, IGF-II and the IGF-I receptor. In the current invention, human IGFBP-3 has been genetically modified so that its affinity for IGF-I and IGF-II is greatly reduced, and it can act only through this novel direct mechanism. These human IGFBP-3 mutants still can inhibit DNA synthesis and stimulate apoptosis, and have been shown to induce apoptosis in human prostate cancer cells. The current invention could selectively exert antiproliferative action without interfering with IGF actions, and may have therapeutic uses as an antitumor

A Novel DNA Methyltransferase Assay System With High Throughput/ Automation Potential

K. Robertson, T. Yokochi (NCI)

[DHHS Reference No. E-030-02/0 filed 14 Jan 2002]

It is now believed that unregulated cell growth is due to aberrant gene expression in cells caused by deletion, mutation, or silencing of one or more critical growth regulatory proteins. The latter method, gene silencing, is mediated by DNA methylation, or the addition of methyl groups to cytosine residues at critical gene expression control regions.

The current invention embodies a novel and highly sensitive assay for detecting DNA methyltransferase activity, which catalyzes the addition of methyl groups to DNA. Treatment with DNA methyltransferase inhibitors in a clinical setting might lead to expression of silenced gene(s) and restoration of controlled cell growth. Huge numbers of compounds must be screened to identify ones that are active against DNA methyltransferases. The assay embodied in the current invention represents the first such assay adaptable for highthroughput and/or automated screening of potential DNA methyltransferase inhibitors. This assay also is fast, easy, reproducible, and highly sensitive.

Generation and Use of Tc1 and Tc2 Cells

D. Fowler (NCI), U. Jung (NCI), J. Medin (NINDS), R. Gress (NCI), A. Erdmann (NCI), B. Levine, and C. June

[U.S. Provisional Patent Application 60/336,473 filed 31 Oct 2001]

Allogeneic stem cell transplantation represents a potentially curative treatment option for patients with both hematologic and solid cancers, and for patients with other non-malignant conditions. However, the clinical application of allogeneic stem cell transplantation is limited by T cell immune reactions.

The current invention embodies a method for enrichment of donor T cells of Tc1 and Tc2 phenotypes by in vitro culture. This method represents a significant advance in terms of T cell numbers produced, level of cytokine polarization, and efficacy of in vivo effects. In murine transplantation models, this method greatly reduces graft-versus-host disease (GVHD) associated with donor CD8 cell administration. Murine Tc2 cells generated by this method are particularly potent in abrogating graft rejection by a mechanism that does not involve GVHD. In addition, this method can generate Tc1 and Tc2 cells that mediate graft-versus-tumor (GVT) effects against murine breast cancer and murine leukemia. The Tc1 and Tc2 cells produced by this method are also amenable to insertion of a suicide gene, which represents a potential strategy for mediating potent allogeneic GVT effects, with subsequent reversal of T cell mediated GVHD. Allogeneic transplantation using Tc1 and Tc2 cells generated via this method may therefore represent an approach to increase the anti-tumor efficacy and reduce the GVHD-toxicity of allogeneic stem cell transplantation, and to extend allogeneic transplantation to those patients lacking an HLA-matched sibling.

Dated: March 7, 2002.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 02-6062 Filed 3-12-02; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: March 7, 2002.1

Time: 9:00 AM to 5:00 PM.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.

Contact Person: Joseph Kimm, PHD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5178 MSC 7844, Bethesda, MD 20892. (301) 435– 1249.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.

Date: March 7, 2002.

Time: 1:00 PM to 2:00 PM.

 $\ensuremath{\mathit{Agenda}}$: To review and evaluate grant applications.

Place: NIH, Rockledge 2, Bethesda, MD 20892. (Telephone Conference Call).

Contact Person: Betty Hayden, PHD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4206, MSC 7812, Bethesda, MD 20892. (301) 435– 1223. haydenb@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333. 93.337, 93.393–93.396, 93.837–93.844, 93– 846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

¹ Editorial Note: This document was received at the Office of the Federal Register on March 8, 2002.

Dated: March 5, 2002. **LaVerne Y. Stringfield,**

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 02-6059 Filed 3-12-02; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute: Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel, Gems Phase II Review.

Date: April 2, 2002.

 $\it Time: 9:00~AM$ to 12:00 PM.

Agenda: To review and evaluate grant applications.

Place: Hilton—Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910. Contact Person: Zoe E. Huang, MD, Review

Branch, Division of Extramural Affairs,
National Heart, Lung, and Blood Institute,
Bethesda, MD 20892–7924. 301–435–0314.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Disease Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)

Dated: March 5, 2002.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 02-6058 Filed 3-12-02; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National institute of Environmental Health Sciences; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel, Review of Conference Grants (R13s).

Date: April 2, 2002.

Time: 2:00 PM to 2:30 PM.

Agenda: To review and evaluate grant applications.

Place: NIEHS-East Campus, Building 4401, Conference Room 3446, Research Triangle Park, NC 27709. (Telephone Conference Call)

Contact Person: RoseAnne M McGee, BS, Associate Scientific Review Administrator, Scientific Review Branch, Office of Program Operations, Division of Extramural Research and Training, Nat. Inst. of Environmental Health Sciences, Research Triangle Park, NC 27709, 919/541–0752.

Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel, Review of Conference Grants (R13s).

Date: April 3, 2002.

Time: 11:30 AM to 12:00 PM.

Agenda: To review and evaluate grant applications.

Place: NIEHS-East Campus, Building 4401, Conference Room 3446, Research Triangle Park, NC 27709. (Telephone Conference Call).

Contact Person: RoseAnne M McGee, BS, Associate Scientific Review Administrator, Scientific Review Branch, Office of Program Operations, Division of Extramural Research and Training, Nat. Inst. of Environmental Health Sciences, Research Triangle Park, NC 27709, 919/541–0752.

Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel, Review of Conference Grants (R13s).

Date: April 3, 2002.

Time: 1:00 PM to 1:30 PM.

Agenda: To review and evaluate grant applications.

Place: NIEHS-East Campus, Building 4401, Conference Room 3446, Research Triangle Park, NC 27709. (Telephone Conference Call).

Contact Person: RoseAnne M McGee, BS, Associate Scientific Review Administrator, Scientific Review Branch, Office of Program Operations, Division of Extramural Research and Training, Nat. Inst. of Environmental Health Sciences, Research Triangle Park, NC 27709. 919/541–0752.

Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel, Review of Conference Grants (R13s).

Date: April 3, 2002.

Time: 2:00 PM to 2:30 PM.

Agenda: To review and evaluate grant applications.

Place: NIEHS-East Campus, Building 4401, Conference Room 3446, Research Triangle Park, NC 27709. (Telephone Conference Call).

Contact Person: RoseAnne M McGee, BS, Associate Scientific Review Administrator, Scientific Review Branch, Office of Program Operations, Division of Extramural Research and Training, Nat. Inst. of Environmental Health Sciences, Research Triangle Park, NC 27709. 919/541–0752.

Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel, Review of Conference Grants (R13s).

Date: April 4, 2002.

Time: 1:00 PM to 1:30 PM.

Agenda: To review and evaluate grant applications.

Place: NIEHS-East Campus, Building 4401, Conference Room 122, 79 Alexander Drive, Research Triangle Park, NC 27709, (Telephone Conference Call).

Contact Person: RoseAnne M McGee, BS, Associate Scientific Review Administrator, Scientific Review Branch, Office of Program Operations, Division of Extramural Research and Training, Nat. Inst. of Environmental Health Sciences, Research Triangle Park, NC 27709, 919/541–0752.

(Catalogue of Federal Domestic Assistance Program Nos. 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing; 93.115, Biometry and Risk Estimation— Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences, National Institutes of Health, HHS).

Dated: March 7, 2002.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 02-6052 Filed 3-12-02; 8:45 am]

BILLING CODE 4410-01-M